Iantrek announced the close of a $42 million Series C financing round that will fund the US commercial launch of AlloFlo Uveo, a first-of-its-kind surgical solution targeting the uveoscleral pathway, as well as broader pipeline expansion. 

“Our mission is to address a major unmet need in glaucoma care, and this fundraise marks a pivotal moment in helping us achieve it,” said Adam Szaronos, CEO of Iantrek. “More than 2.5 million eyes in the United States are experiencing waning efficacy from previous MIGS procedures targeting the trabecular pathway. AlloFlo Uveo enables access to the uveoscleral pathway, the eye’s other natural drainage system—much like giving a thoracic surgeon the ability to enhance the second lung.”

Clinical Evidence and Early Adoption

In 2025, the American Academy of Ophthalmology published a peer-reviewed study in Ophthalmology Science demonstrating long-term efficacy and safety in patients having undergone bio-reinforced cyclodialysis with AlloFlo Uveo. Key findings after 2 years included a mean reduction of IOP of 34%, use of IOP-lowering medications decreased by >60%, and no serious product-related adverse events reported.

“With approximately 3,000 procedures performed through its early access program, surgeon demand for uveoscleral pathway access is clear,” said Sean Ianchulev, MD, MPH, professor of ophthalmology at the New York Eye and Ear of Mount Sinai and Chairman of the Board of Iantrek. “Iantrek’s bio-interventional approach is currently the only surgical solution targeting this major outflow pathway with the highest therapeutic index in glaucoma treatment.”

Iantrek’s portfolio includes AlloFlo Uveo, AlloSert Uveo, and C.Rex—next-generation bio-interventional and microinterventional solutions designed to improve surgical precision, and access to the eye’s natural outflow pathways. AlloFlo Uveo is the first allogeneic graft tailored for durable implantation and bio-integration in ophthalmic applications. The company has also completed first-in-human trials for its next bio-interventional product, with commercial launch expected in 2026.

The Series C was led by US Venture Partners (USVP), joined by aMoon Fund, along with existing investors Visionary Ventures, Sectoral Asset Management, Radius Special Situations Fund, and Civilization Ventures.